CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 63 enrolled
Drug / intervention
TIV +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03022422
NCT03022422Phase 4Completed
CompareCT.gov

Protective Mechanisms Against a Pandemic Respiratory Virus: B-Cell, T-cell, and General Immune Response to Seasonal Influenza Vaccine. Year 3, 2011

Stanford University·interventional·Posted Jan 16, 2017·Updated Aug 21, 2017

In Brief

A Phase 4 clinical trial evaluating TIV and High-Dose TIV for Influenza. Completed, enrolled 63 participants.

Detailed Summary

This study will investigate markers, mechanisms and define general predictors for immunological health by comparing influenza vaccine responses in monozygotic and dizygotic twins.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
Countries--
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 16, 2017
Enrollment StartSep 1, 2011
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 9.5 years ago

Interventions

TIVbiological

Influenza Virus Vaccine Suspension for Intramuscular Injection

High-Dose TIVbiological

High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe for intramuscular injection